Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2017—Horizon Discovery announced progress of its gene and cell therapy platform for contract service and therapeutic applications. The offering will make use of Horizon’s suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells and primary human lymphocytes.
August 2017—Thermo Fisher Scientific introduced its Thermo Scientific Cascadion SM Clinical Analyzer at EuroMedLab 2017 in Athens, Greece.
August 2017—GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier following the publication of a study in European Urology (Seiler R, et al. Epub ahead of print April 5, 2017) supporting its development and validation. The company believes Decipher Bladder is the first commercially available clinical assay to subtype muscle-invasive bladder cancer with a high degree of accuracy.
August 2017—The Stago group has completed the acquisition of HemoSonics LLC, a company that develops point-of-care testing solutions and is based in Charlottesville, Va., with facilities in Durham, NC.
August 2017—Ortho Clinical Diagnostics launched its Vitros NephroCheck test, a fully automated risk assessment tool for predicting acute kidney injury. The test has received CE mark clearance and is available for purchase in Europe and for use on Ortho’s Vitros Systems.
August 2017—Luminex received FDA clearance for the Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.
August 2017—Genoptix and Bionano Genomics announced an exclusive agreement to co-develop information-rich diagnostics for selected hematologic oncology indications in the United States using Bionano’s Saphyr system.
August 2017—Binding Site’s Immunologicals Group has added a number of monoclonal antibodies used for the clinical testing of human immunodeficiency virus to its line of in vitro diagnostic manufacturing and clinical research applications. The HIV P24 275, HIV P24 114, and HIV P24 9.23.11.8.9.4 anti-human monoclonal antibodies have been designed for use as an integral component within a number of enzyme immunoassay testing procedures.
August 2017—Techlab Inc. received FDA clearance for its E. Histolytica Quik Chek test, a rapid diagnostic test that specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic Entamoeba dispar.
August 2017—Siemens Healthineers has entered into a definitive agreement to acquire Epocal, a subsidiary of Alere. Epocal develops and provides point-of-care blood diagnostic systems for health care enterprises, including the epoc Blood Analysis System, a handheld, wireless testing solution.
